Medifast (MED) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Voting matters and shareholder proposals
Seven nominees are up for election to the board of directors for one-year terms expiring in 2027.
Ratification of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 is proposed.
Advisory approval of named executive officer compensation is on the agenda.
Approval of the Amended and Restated 2012 Share Incentive Plan is proposed.
Other business may be transacted as may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting for all seven director nominees, each to serve a one-year term.
Executive compensation and say-on-pay
Advisory vote on executive compensation for named executive officers is included.
Board recommends approval of the Amended and Restated 2012 Share Incentive Plan.
Latest events from Medifast
- Q2 2026 revenue fell 27.6% to $76.4M, net loss was $3.1M, but per-coach productivity rose 41%.MED
Q2 2026 - Revenue and coach count dropped sharply, but productivity gains and new strategies aim to drive recovery.MED
Q1 2026 - Shareholders will vote on expanding the share plan and a new 12-month holding rule for executives.MED
Proxy filing - Annual meeting to vote on directors, auditor, executive pay, and expanded share plan.MED
Proxy filing - Coach productivity rose in Q4 2025 as the business pivots to metabolic health and new products.MED
Q4 2025 - Annual meeting to vote on directors, auditor, compensation, and share plan amid major transformation.MED
Proxy Filing - Revenue dropped 43% but gross margin and cash remain strong as GLP-1 investments accelerate.MED
Q2 2024 - Q3 revenue dropped 40.6% as coach count fell, but new products and strong cash support future plans.MED
Q3 2024 - Q4 2024 revenue at guidance high, cost savings and new products offset GLP-1 market headwinds.MED
Q4 2024